Colin D. Godwin - Concepedia

Author

Colin D. Godwin

Fred Hutch Cancer Center ORCID

Also Known As

C D Godwin, C. Godwin, Colin D. Godwin, Colin Godwin

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Fred Hutch Cancer Center University of Washington Hospital Universitario Doctor Peset Humanitas University Ospedale Papa Giovanni XXIII

About

Colin D. Godwin is an author at Fred Hutch Cancer Center specializing in medicine, bipolar disorder, and psychiatry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	650
2	Health Sciences	2	2	150
3	Natural Sciences	1	1	246
4	Social Sciences	1	1	22
5	Blood Transplantation	1	1	39

Colin D. Godwin

Publications

811

Citations

H-Index

Page 1

	Year	Citations
UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit Mathew J. Garnett, Jörg Mansfeld, Colin D. Godwin, Nature Cell Biology Protein FunctionMitotic ExitCell DivisionUbiquitin ChainsNatural Sciences	2009	246
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation Roland B. Walter, Boglarka Gyurkocza, B. Storer, Leukemia Hematological MalignancyTransplantationMarrow TransplantationImmunologyHematology	2014	211
Lithium-carbamazepine neurotoxicity and risk factors Sashi Shukla, Colin D. Godwin, Mary Miller American Journal of Psychiatry Psychoactive DrugPsychiatryAddictionMedicineDrug Combination	1984	111
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study Sandy W. Wong, Noffar Bar, Laura París, Blood	2022	67
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm Raffaele Palmieri, Megan Othus, Anna B. Halpern, Journal of Clinical Oncology	2020	49
Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission Roland B. Walter, Brenda M. Sandmaier, Barry E. Storer, Biology of Blood and Marrow Transplantation Hematological MalignancyTransplantationMarrow TransplantationMorphological RemissionMedicine	2014	39
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study Noffar Bar, María‐Victoria Mateos, Paz Ribas, Blood	2023	31
Consistent dexamethasone suppression test results with mania and depression in bipolar illness Colin D. Godwin, L B Greenberg American Journal of Psychiatry Dexamethasone Suppression TestsPsychopathologyPatients Dst ResultsPsychiatryMood Symptom	1984	22
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy Colin D. Godwin, George S. Laszlo, Salvatore Fiorenza, Leukemia ImmunoengineeringImmunologyTumor ImmunityAntigen ProcessingAutoimmunity	2021	21
P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY Sandy W. Wong, Noffar Bar, María‐Victoria Mateos, HemaSphere	2023	14

Page 1